Teva Pharmaceutical Industries

Teva does not have a standalone investment team like a corporate venture capital unit. Strategic investments, licensing deals, and co-development partnerships are driven by the business development and corporate strategy functions under the CEO. Board-level oversight includes Amir Elstein, representing the founding family, and Elliott Investment Management appointees as of 2025.

Teva sources partnerships through its internal R&D scouting teams, industry conferences, and its deep relationships with generics and specialty pharmacy supply chains. Partnerships like the Sanofi duvakitug deal and the Blackstone Life Sciences co-funding arrangement reflect a mix of late-stage pipeline licensing and structured manufacturing collaboration, rather than early-stage venture bets.

Teva operates almost entirely through direct balance-sheet investments — co-development agreements, licensing pacts, and manufacturing joint ventures. The firm does not publicly disclose commitments to third-party venture funds, distinguishing its investment posture from that of pharma companies that maintain dedicated corporate VC arms.

The Elstein family provided foundational capital when Teva was established in 1901 and has maintained board representation across multiple generations. Amir Elstein currently serves as a director, preserving a direct lineage connection to the firm's founding ownership structure. The family's ongoing role is exercised through board governance rather than executive management.

Elliott Investment Management, the activist hedge fund, secured board representation at Teva in 2025. The firm is pushing for changes in capital allocation, pipeline prioritization, and operational efficiency. This activist presence introduces an external discipline layer to Teva's investment decision-making that a standalone corporate venture unit would not face.

Teva does not publicize a co-investment program in the institutional LP sense. Its collaborative model involves partnering with financial sponsors like Blackstone Life Sciences on specific development-stage assets. These are structured as bilateral deals tied to product economics rather than commingled fund vehicles.

Teva operates the Teva Cares Foundation as a separate philanthropic entity focused on global health access, particularly in underserved markets. The foundation's funding and governance are distinct from Teva's commercial balance sheet, though its mission aligns with Teva's generics-focused public-health positioning.